Drugs / rmhTNF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05755685 | Feb 2023 → Jan 2024 | colorectal cancer, peritoneal carcinomatosis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rmhTNF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05755685 ↗ |
| Known as | Recombinant Modified Human Tumor Necrosis Factor | “Recombinant Modified Human Tumor Necrosis Factor (rmhTNF)” NCT05755685 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Modified Human Tumor Necrosis Factor (rmhTNF)” NCT05755685 ↗ |
| Route | Other | “intraperitoneal heat perfusion” NCT05755685 ↗ |